Megan May, PharmD, BCOP, FHOPA, FAPO

home / authors / megan-may-pharmd-bcop-fhopa-fapo

Articles

3d rendering of Bispecific antibodies or BsAbs have two distinct binding domains that can bind to two antigens or two epitopes of the same antigen simultaneously.

Real-World Data on Expanding Step-Up Dosing Administration of Bispecific T-Cell Engagers in the Outpatient Setting

Emilie Aschenbrenner, PharmD, BCOP;Megan May, PharmD, BCOP, FHOPA, FAPO

June 13th 2025

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

HER2 breast cancer -- Image credit: David A Litman | stock.adobe.com

Advances in the Management of HR+/HER2– Ultralow and -Low Metastatic Breast Cancer: New Horizons and Treatment Frontiers

Megan May, PharmD, BCOP, FHOPA, FAPO; Rose DiMarco, PharmD, BCPS, BCOP

April 18th 2025

Antibody-drug conjugates have revolutionized metastatic breast cancer treatment and classification.

Patient receiving cancer treatment infusion -- Image credit: UlrikaArt | stock.adobe.com

Lurbinectedin and Tarlatamab: Emerging Second-Line Therapies in the SCLC Space

Gillian McGovern, Associate Editor;Megan May, PharmD, BCOP, FHOPA, FAPO

March 25th 2025

Megan May, PharmD, BCOP, FHOPA, FAPO, discusses lurbinectedin and tarlatamab and what ongoing research in the small cell lung cancer (SCLC) space entails.

Small cell lung cancer -- Image credit: LASZLO | stock.adobe.com

Despite New Agents in SCLC, Prolonged Survival Remains an Unmet Need

Gillian McGovern, Associate Editor;Megan May, PharmD, BCOP, FHOPA, FAPO

March 21st 2025

After decades without improvements, an expert with Baptist Health described the small cell lung cancer (SCLC) space as “exciting” following multiple innovations in the past few years.